Why the study?
What clinical and therapeutic factors are associated with B-type natriuretic peptide (BNP) concentrations in primary care patients with cardiovascular risk factors?
What clinical and therapeutic factors are associated with B-type natriuretic peptide (BNP) concentrations in primary care patients with cardiovascular risk factors?
BNP concentrations in primary care are significantly influenced by age, sex, beta-blocker use, prior MI, and arrhythmias, which must be considered when using BNP as a screening tool for ventricular dysfunction.
Answers are grounded in this paper and cite their sources.
These factors warrant caution when interpreting BNP for primary care screening; hypothesis-generating for adjusted thresholds in prospective studies.
BACKGROUND: An effective prevention strategy for heart failure in primary care requires a reliable screening tool for asymptomatic ventricular dysfunction. Preliminary data indicate that B-type natriuretic peptide (BNP) may be suitable for this task. However, for the most effective use of this peptide, the interrelationships between associated risk factors and their therapies on BNP, and in particular their magnitude of effect, needs to be established in a large primary care population. Therefore, the objective of the study was to establish the extent of the association between BNP, cardiovascular risk factors and their therapies. METHODS: BNP measurement and clinical review was preformed on 1122 primary care patients with cardiovascular risk factors. Multivariate analyses identified significant associates of BNP concentrations which were further explored to establish the magnitude of their association. RESULTS: Associates of BNP were age (1.36-fold increase in BNP/decade), female (1.28), β-blockers (1.90), myocardial infarction (1.36), arrhythmia (1.98), diastolic blood pressure; all p<0.01. A novel method was devised that plotted median BNP per sliding decade of age for the various combinations of these principal associates. CONCLUSIONS: The data presented underline the importance of considering several clinical and therapeutic factors when interpreting BNP concentrations. Most of these variables were associated with increased concentrations, which may in part explain the observed false-positive rates for detecting ventricular dysfunction using this peptide. Furthermore, the design of studies or protocols using BNP as an endpoint or a clinical tool should take particular account of these associations. This analysis provides the foundation for age, risk factor and therapy adjusted reference ranges for BNP in this setting.
No takes yet. Share an insight, caveat, or question.
Conlon et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: